

Children's Mercy Kansas City

SHARE @ Children's Mercy

Posters

10-2023

Increasing vaccination rates of 23-valent pneumococcal polysaccharide vaccine among patients at high-risk for invasive pneumococcal disease.

Edward Lyon

Tracey Wetzel

Ann L. Wirtz

Douglas Swanson

Rachel Moran

See next page for additional authors

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/posters>



Part of the [Infectious Disease Commons](#), and the [Pediatrics Commons](#)

Authors

Edward Lyon, Tracey Wetzel, Ann L. Wirtz, Douglas Swanson, Rachel Moran, Jessica Peters, Christine Symes, Liset Olarte, and Rana El Feghaly




Increasing vaccination rates of 23-valent pneumococcal polysaccharide vaccine among patients at high-risk for invasive pneumococcal disease

Edward Lyon¹ DO MA, Tracey Wetzel¹ RN BSN CPN, Ann L Wirtz¹ PharmD BCPPS, Douglas Swanson¹ MD, Rachel Moran² BA, Jessica Peters³ MEd, Christine A Symes¹ RN MSN CPN CPNP-BC, Liset Olarte¹ MD MSc, Rana E. El Feghaly¹ MD MSCI

¹Infectious Diseases Division Children's Mercy Hospital Kansas City MO; ²Integrated Care Solutions (ICS) Children's Mercy Hospital Kansas City MO; ³Office of Patient Experience Children's Mercy Hospital Kansas City MO

Background	AIM
<ul style="list-style-type: none"> Pneumococcal disease causes significant morbidity and mortality in children Routine childhood vaccines provide protection via PCV 13/15 Certain patients are at higher risk of invasive pneumococcal disease (IPD) <ul style="list-style-type: none"> Immunocompromising conditions Chronic medical conditions Expanded protection is recommended for those who qualify <ul style="list-style-type: none"> 23 valent polysaccharide vaccine (PPSV23) 	<p style="text-align: center;">Increase PPSV23 vaccination rates among eligible patients in both the inpatient and outpatient infectious diseases settings from a baseline of 44% to 55% by October 2024</p>

Methods	
<ul style="list-style-type: none"> Collaboration with Integrated Care Solutions to generate baseline data for patients who qualify for PPSV23 at the time of ID engagement (outpatient and inpatient) October 2022 Multidisciplinary team formed: ID providers (physicians, advanced practice providers and nursing staff, Pharmacist, patient advocate) Outcome Measure <ul style="list-style-type: none"> Rate of PPSV23 vaccination in qualifying patients with ID encounter Process Measure <ul style="list-style-type: none"> Updates on tracking list of PPSV23 and PCV13/15 eligibility Balancing Measure <ul style="list-style-type: none"> Rate of adverse events and delayed discharges 	<ul style="list-style-type: none"> Root cause analysis (Fig. 1), driver diagram (Fig. 2) and PICK chart developed to understand, and guide planned interventions Plan-Do-Study-Act Cycles <ol style="list-style-type: none"> Formation of team and discussion at weekly divisional huddle Updated electronic medical record report and begin 2-way communication between clinic and provider Badge buddy and shared documentation phrase Add vaccine section to immunocompromised tracking list



Results
<ul style="list-style-type: none"> Inconsistency in percentage of qualifying patients being immunized with PPSV23 prior to October 2022 There was a shift in the rate of patients vaccinated for PPSV23 in October 2022, shortly after our team formed (Fig. 3) Most qualifying patients were immunocompromised, and teams were not comfortable administering the vaccine at the time of admission

Conclusion
<ul style="list-style-type: none"> Electronic medical record synchronization with outside systems is difficult, making vaccine recommendations hard Multi-step process of eligibility for PPSV23 will be streamlined with the recent approval and introduction of PCV20 Need for collaborative efforts between all parties caring for high-risk children and adolescents to maximize protection against IPD



Contact information:
Eddie Lyon, DO MA
erlyon@cmh.edu

